Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Quadruple Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests as First-line Treatment for Helicobacter Pylori Infection

NCT05718609 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT05718609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05718609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Quadruple Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests as First-line Treatment for Helicobacter Pylori Infection
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Phase 4
Overall status
Unknown status
Start date
March 1, 2023
Completion date
June 30, 2024
Enrollment
855 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infection